Issue Date: August 29, 2016
Pfizer will acquire AstraZeneca business
Pfizer has agreed to acquire AstraZeneca’s late-stage small-molecule antibiotics business, primarily outside the U.S., for $725 million and up to $850 million in future payments. The business includes Zavicefta, recently approved in the European Union; the marketed products Merrem and Zinforo; and two products in clinical development. AstraZeneca spun off its antibiotics R&D efforts as Entasis Therapeutics last year.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society